Last updated on February 2018

Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Brief description of study

The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma

Clinical Study Identifier: NCT03200691

Contact Investigators or Research Sites near you

Start Over

Shixiu Wu, MD

Hangzhou Cancer Hospital
Hangzhou, China
  Connect »